Nissha Co., Ltd. (hereinafter, “Company”) hereby announces that the share acquisition of Zonnebodo Pharmaceutical Co., Ltd. (hereinafter, “Zonnebodo Pharmaceutical”) has been completed and making it a subsidiary dated as of November 25, 2019, in accordance with the “Notice Regarding the Acquisition of Zonnebodo Pharmaceutical Co., Ltd.” previously disclosed dated as of November 8, 2019.

Zonnebodo Pharmaceutical’s history stretches back eighty years, and it is engaged in manufacturing and marketing authorization holder of in-house developed prescription pharmaceuticals (brand-name drugs) and quasi drugs. With this acquisition, the Company obtains the business foundation necessary to put film type of pharmaceuticals on the market. By means of the core technologies it has cultivated since it was founded, as well as other innovations, the Company aims to make a corporate social contribution to the pharmaceutical market, as it has in other markets, in such a way as to enrich people’s lives.

The impact of this transaction on the Company’s consolidated results for the current fiscal year is expected to be negligible. Going forward, if revisions to business forecasts or the announcement of other matters become necessary, we will make prompt disclosure of the same.